PMID- 32603199
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1029-2330 (Electronic)
IS  - 1026-7158 (Linking)
VI  - 28
IP  - 10
DP  - 2020 Dec
TI  - How to use macrophages to realise the treatment of tumour.
PG  - 1034-1045
LID - 10.1080/1061186X.2020.1775236 [doi]
AB  - Macrophages (Mo) are immune cells with natural phagocytic ability and play an 
      important role in tumorigenesis, development and metastasis. Mo play a dual role 
      of tumour inhibition and tumour promotion in tumour development due to their two 
      different phenotypes. Mo in the tumour microenvironment have long been referred 
      to as tumour-associated Mo (TAMs). Mo are mainly involved in tumour resistance, 
      cancer metastasis and mediating immunosuppression. Nowadays, Mo and Mo membranes 
      have been widely used in drug delivery systems (DDSs) because of their good 
      biocompatibility, natural phagocytosis and their important role in tumour 
      development. In this review, from the perspective of Mo's role in tumour 
      development, we present strategies and drugs of Mo targeting and focusing on the 
      several types of biomimetic nanoparticles constructed by Mo and Mo membranes in 
      tumour therapy, and discuss the problem of this delivery system in present 
      research and future directions.
FAU - Zhang, Xiaoyu
AU  - Zhang X
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Li, Weinan
AU  - Li W
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Sun, Jialin
AU  - Sun J
AD  - Biological Science and Technology Department, Heilongjiang Vocational College for 
      Nationalities, Harbin, P.R. China.
FAU - Yang, Zhixin
AU  - Yang Z
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Guan, Qingxia
AU  - Guan Q
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Wang, Rui
AU  - Wang R
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Li, Xiuyan
AU  - Li X
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Li, Yongji
AU  - Li Y
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Feng, Yufei
AU  - Feng Y
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
FAU - Wang, Yanhong
AU  - Wang Y
AD  - School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200703
PL  - England
TA  - J Drug Target
JT  - Journal of drug targeting
JID - 9312476
SB  - IM
MH  - Drug Delivery Systems/*methods
MH  - Drug Resistance, Neoplasm/immunology
MH  - Humans
MH  - Macrophages/immunology
MH  - Neoplasms/*drug therapy
MH  - Phagocytosis/immunology
MH  - Phenotype
MH  - Tumor Microenvironment/immunology
MH  - Tumor-Associated Macrophages/*immunology
OTO - NOTNLM
OT  - Macrophages
OT  - drug delivery system
OT  - macrophages membrane
OT  - targeting strategy
OT  - tumour therapy
EDAT- 2020/07/01 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/07/01 06:00
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/07/01 06:00 [entrez]
AID - 10.1080/1061186X.2020.1775236 [doi]
PST - ppublish
SO  - J Drug Target. 2020 Dec;28(10):1034-1045. doi: 10.1080/1061186X.2020.1775236. 
      Epub 2020 Jul 3.